CNBC August 1, 2024
Key Points
– Eli Lilly’s weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data.
– The findings add to mounting evidence that Zepbound and other highly popular GLP-1 drugs have health benefits beyond promoting weight loss and regulating blood sugar.
– Patients who took Zepbound were 38% less likely to be hospitalized, need to increase their heart failure medication or die because of heart complications compared with those who received a placebo.
Eli Lilly‘s weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company released Thursday.
The findings add to mounting...
Today's Sponsors
Today's Sponsor